---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-017082"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:47:02.030598+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evofem Biosciences extends maturity of Adjuvant convertible notes by six months

## Summary
- Fourth Amendment to Securities Purchase Agreement dated April 10, 2026 with Adjuvant Global Health Technology Fund.
- Notes now due six months after April 10, 2026 (approx. Oct 10, 2026), or upon change of control or acceleration.
- No prepayment of notes allowed before that six-month date without Adjuvant's prior written consent.
- Amendment updates maturity definition in Section 3.1 of the Purchase Agreement.

## SEC filing metadata
- accession: 0001493152-26-017082
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-017082
- JSON: https://secwatch.observer/filing/0001493152-26-017082.json
- Plain text: https://secwatch.observer/filing/0001493152-26-017082.txt

## Source-grounded claims
- claim_id: d18db34d19d2c442097325b0506fcc2261255db3
  claim: Evofem Biosciences, Inc. amended Fourth Amendment with Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. (together, Adjuvant) (effective 2026-04-10).
  evidence_excerpt: On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.